No Data
Innovative drug concepts are generally rising, Beigene (06160) rose 3.14%. Institutions pointed out that overseas authorization and heavy innovation will be the catalyst for industry investment.
Innovative drug concept rose, Remegen (09995) rose by 4.14%, Beigene (06160) rose by 3.14%, Akeso (09926) rose by 1.84%, Innovent bio (01801) rose by 1.82%, Hutchmed (china) (00013) rose by 1.82%, Frontage (01521) rose by 1.35%, Canbridge Life Sciences-B (02162) rose by 0.63%, Innocare (09969) rose by 0.45%. Sinolink Securities indicated that the performance of the innovative drug companies has shown a clear trend of improvement based on the disclosed interim reports. Beigene and Hutchmed (china) pharmaceutical both performed well.
HKEx news | Remegen (09995) rose more than 5%. The phase III trial of Taqtelekumab in myasthenia gravis met its primary endpoint. It plans to apply for listing.
Remegen (09995) rose more than 5%, as of the time of writing, it rose 5.14%, to HKD 14.72, with a turnover of 5.7904 million Hong Kong dollars.
Zhītōng Hǎngǔ zǎo zhīdào | The implementation plan for the high-quality development of the power distribution network has been issued, and the broad money supply (M2) balance increased by 6.3% year-on-year at the end of July.
The National Energy Administration has issued the "Implementation Plan for High-quality Development of Distribution Network (2024-2027)".
Remegen (688331.SH): Thymalfasin has achieved the primary endpoint of phase III clinical study for the treatment of myasthenia gravis.
On August 13th, Gelon Hui announced that Remegen Bio (688331.SH) independently developed the innovative drug RC18, a BLyS/APRIL dual-target fusion protein called Taitsipu (Trade name: Tai Ai), has achieved the main clinical trial endpoint of the planned design for phase III clinical trials for the treatment of generalized myasthenia gravis (gMG). Taitsipu has already completed phase III clinical trials in China for the treatment of myasthenia gravis, achieving the main clinical trial endpoint of the planned design. Clinical study results show that Tai Ai can effectively and sustainably improve the clinical symptoms of patients with generalized myasthenia gravis, demonstrating good efficacy.
Remegen appoints He Ruyi as Chief Global Strategy Officer.
Remegen (09995) announced that Remegen Pharmaceutical (Yantai) Co., Ltd. (hereinafter referred to as "the Company") has appointed Mr. He Ruyi as the Chief Global Strategy Officer of the Company. Mr. He Ruyi will continue to serve as a director of the Company and a core technical employee, but will no longer serve as the Chief Medical Officer and senior management personnel of the company.
Remegen (09995) has appointed He Ruyi as Chief Global Strategy Officer.
Remegen (09995) announced that Remegen Pharmaceutical (Yantai) Co., Ltd. (hereinafter referred to as 'the Company')...
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
No Data
